Journal of Blood & Lymph

Department of Hematology, University of Santo Tomas Hospital, Espana, Manila, Philippines

Publications

• Research Article   
  Use of Low-Dose Decitabine with or without Tyrosine Kinase Inhibitors in Advanced Phase Chronic Myelogenous Leukemia: A Systemic Review and Metaanalysis
  Author(s): Maureen Via M Comia*, Charles Eryll S Sy and Jomell C Julian
  
  Reasoning: Movement of Persistent Myelogenous Leukemia (CML) to further developed stages can include hypermethylation, which is connected to opposition or prejudice to imatinib. This hypermethylation has likewise been viewed as a negative prognostic component free of imatinib reaction and from CML stage, consequently decitabine, a hypomethylating specialist, can be an appealing treatment choice for cutting edge stage CML. Objective: This foundational survey and meta-examination expects to research the job of low-portion decitabine among patients with cutting edge stage CML. Technique: This was performed by the articulation of Favored Announcing Things for Orderly Surveys and Meta-Examinations (PRISMA). Results: Four (4) studies from 86 articles screened were qualified to be evaluated in this fundamental .. Read More»
  DOI: 10.37421/2165-7831.2023.13.305

  Abstract HTML PDF